Plasma-Treated Solutions (PTS) in Cancer Therapy

dc.bibliographicCitation.firstPage1737eng
dc.bibliographicCitation.issue7eng
dc.bibliographicCitation.journalTitleCancerseng
dc.bibliographicCitation.volume13eng
dc.contributor.authorTanaka, Hiromasa
dc.contributor.authorBekeschus, Sander
dc.contributor.authorYan, Dayun
dc.contributor.authorHori, Masaru
dc.contributor.authorKeidar, Michael
dc.contributor.authorLaroussi, Mounir
dc.date.accessioned2022-03-22T11:30:43Z
dc.date.available2022-03-22T11:30:43Z
dc.date.issued2021
dc.description.abstractCold physical plasma is a partially ionized gas generating various reactive oxygen and nitrogen species (ROS/RNS) simultaneously. ROS/RNS have therapeutic effects when applied to cells and tissues either directly from the plasma or via exposure to solutions that have been treated beforehand using plasma processes. This review addresses the challenges and opportunities of plasma-treated solutions (PTSs) for cancer treatment. These PTSs include plasma-treated cell culture media in experimental research as well as clinically approved solutions such as saline and Ringer’s lactate, which, in principle, already qualify for testing in therapeutic settings. Several types of cancers were found to succumb to the toxic action of PTSs, suggesting a broad mechanism of action based on the tumor-toxic activity of ROS/RNS stored in these solutions. Moreover, it is indi-cated that the PTS has immuno-stimulatory properties. Two different routes of application are cur-rently envisaged in the clinical setting. One is direct injection into the bulk tumor, and the other is lavage in patients suffering from peritoneal carcinomatosis adjuvant to standard chemotherapy. While many promising results have been achieved so far, several obstacles, such as the standardized generation of large volumes of sterile PTS, remain to be addressed. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/8319
dc.identifier.urihttps://doi.org/10.34657/7357
dc.language.isoengeng
dc.publisherBasel : MDPIeng
dc.relation.doihttps://doi.org/10.3390/cancers13071737
dc.relation.essn2072-6694
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subject.ddc610eng
dc.subject.otherPAMeng
dc.subject.othercold physical plasmaeng
dc.subject.otherlow-temperature plasmaeng
dc.subject.othernonthermal plasmaeng
dc.subject.otheroncologyeng
dc.subject.otherplasma medicineeng
dc.subject.otherplasma-activated mediumeng
dc.subject.otherreactive nitrogen specieseng
dc.subject.otherreactive oxygen specieseng
dc.titlePlasma-Treated Solutions (PTS) in Cancer Therapyeng
dc.typeArticleeng
dc.typeTexteng
tib.accessRightsopenAccesseng
wgl.contributorINPeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
cancers-13-01737-v2.pdf
Size:
7.23 MB
Format:
Adobe Portable Document Format
Description:
Collections